AVE 5026: Clinical Trials

7 trials of AVE 5026, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 37Completed 6, Terminated 1

Follow AVE 5026: new trials by email Literature Review of AVE 5026 trials Research Report on AVE 5026

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
Enoxaparin sodium, Semuloparin sodium, Placebo - Venous Thromboembolism
Phase 3CompletedSanofi10032008-07-012013-01-23
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
Semuloparin sodium, Enoxaparin sodium - Venous Thromboembolism
Phase 3TerminatedSanofi4212008-07-012013-01-23
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
Semuloparin sodium, Enoxaparin, Placebo - Venous Thromboembolism
Phase 3CompletedSanofi11502008-07-012013-01-23
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium - Venous Thromboembolism
Phase 3CompletedSanofi4692008-06-012013-06-14
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
Semuloparin sodium, Enoxaparin sodium, Placebo - Venous Thromboembolism
Phase 3CompletedSanofi23262008-06-012013-01-23
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Semuloparin sodium, Placebo (for semuloparin) - Venous Thromboembolism, Cancer
Phase 3CompletedSanofi32122008-06-012013-01-23
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
Semuloparin Sodium, Enoxaparin sodium, Placebo - Venous Thromboembolism
Phase 3CompletedSanofi44132008-04-012013-12-16

Conditions studied

Venous Thromboembolism (7)  ·  Hip Fractures (1)  ·  Neoplasms (1)  ·  Venous Thrombosis (1)

Sponsors

Sanofi (7)

Countries

Canada (7)  ·  Mexico (7)  ·  Russia (7)  ·  Ukraine (7)  ·  United States (7)  ·  Belarus (6)  ·  Czechia (6)  ·  India (6)  ·  Romania (6)  ·  South Africa (6)  ·  Argentina (5)  ·  Australia (5)  ·  Chile (5)  ·  Colombia (5)  ·  Denmark (5)

Top investigators

Alexander Turpie, MD (3)  ·  William D. Fisher, MD (2)  ·  Ajay Kakkar, Prof., MD, PhD (1)  ·  Alexander G. Turpie (1)  ·  Alexander G. Turpie, MD (1)  ·  Giancarlo Agnelli, MD (1)  ·  Patrick Mismetti, MD (1)

Results publications

PMID 22429800, PMID 22335737, PMID 23539696, PMID 24374549, PMID 33337539

NIH funding

2008 (1)